Therapeutic Indications

Alemtuzumab is indicated for:

Relapsing remitting multiple sclerosis (RRMS)

Irrespective of gender only Adults (18 years old or older)

Alemtuzumab is indicated for adult patients with relapsing remitting multiple sclerosis (RRMS) with active disease defined by clinical or imaging features.

For this indication, the medical literature mentions below treatments (click for details):

Treatment 1: Intravenous - 12 mg/day on 5 consecutive days


Active ingredient Alemtuzumab is contraindicated in the following cases:


No gender/age discrimination

Alemtuzumab is contraindicated in HIV.


No gender/age discrimination

Alemtuzumab was detected in the milk and offspring of lactating female mice.
It is unknown whether alemtuzumab is excreted in human milk. A risk to the suckling newborn/infant cannot be excluded. Therefore, breast-feeding should be discontinued during each course of treatment with LEMTRADA and for 4 months following the last infusion of each treatment course. However, benefits of conferred immunity through breast-milk may outweigh the risks of potential exposure to alemtuzumab for the suckling newborn/infant.


No gender/age discrimination

There is a limited amount of data from the use of alemtuzumab in pregnant women. alemtuzumab should be administered during pregnancy only if the potential benefit justifies the potential risk to the foetus.
Human IgG is known to cross the placental barrier; alemtuzumab may cross the placental barrier as well and thus potentially pose a risk to the foetus. Animal studies have shown reproductive toxicity.
It is not known whether alemtuzumab can cause foetal harm when administered to pregnant women or whether it can affect reproductive capacity.
Thyroid disease poses special risks in women who are pregnant. Without treatment of hypothyroidism during pregnancy, there is an increased risk for miscarriage and foetal effects such as mental retardation and dwarfism. In mothers with Graves’ disease, maternal thyroid stimulating hormone receptor antibodies can be transferred to a developing foetus and can cause transient neonatal Graves’ disease.

Severe active infection

No gender/age discrimination

Alemtuzumab is contraindicated in severe active infection until resolution.